Background: Acute kidney injury (AKI) is a frequent complication in hospitalized patients, especially in those in intensive care units (ICU). The RIFLE classification might be a valid prognostic factor for critically ill cancer patients. The present study aims to evaluate the discriminatory capacity of RIFLE versus other general prognostic scores in predicting hospital mortality in critically ill cancer patients. Methods: This is a single-center study conducted in a cancer-specialized ICU in Brazil. All of the 288 patients hospitalized from May 2006 to June 2008 were included. RIFLE classification, APACHE II, SOFA, and SAPS II scores were calculated and the area under receiver operating characteristic (AROC) curves and logistic multiple regression were performed using hospital mortality as the outcome. Results: AKI, defined by RIFLE criteria, was observed in 156 (54.2%) patients. The distribution of patients with any degree of AKI was: risk, n = 96 (33.3%); injury, n = 30 (10.4%), and failure, n = 30 (10.4%). Mortality was 13.6% for non-AKI patients, 49% for RIFLE ‘R’ patients, 62.3% for RIFLE ‘I’ patients, and 86.8% for RIFLE ‘F’ patients (p = 0.0006). Logistic regression analysis showed that RIFLE criteria, APACHE II, SOFA, and SAPS II were independent factors for mortality in this population. The discrimination of RIFLE was good (AROC 0.801, 95% CI 0.748–0.854) but inferior compared to those of APACHE II (AROC 0.940, 95% CI 0.915–0.966), SOFA (AROC 0.910, 95% CI 0.876–0.943), and SAPS II (AROC 0.869, 95% CI 0.827–0.912). Conclusion: AKI is a frequent complication in ICU patients with cancer. RIFLE was inferior to commonly used prognostic scores for predicting mortality in this cohort of patients.

Keywords:
Acute kidney injury, Intensive care unit, Prognosis, RIFLE, APACHE II
1.
Hoste EA, Kellum JA, Katz NM, Rosner MH, Haase M, Ronco C: Epidemiology of acute kidney injury. Contrib Nephrol 2010;165:1–8.
2.
Uchino S, Kellum JA, Bellomo R, et al: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813–818.
3.
Hilton R: Acute renal failure. BMJ 2006;333:786–790.
4.
Benoit DD, Hoste EA: Acute kidney injury in critically ill patients with cancer. Crit Care Clin 2010;26:151–179.
5.
Joannidis M, Metnitz PG: Epidemiology and natural history of acute renal failure in the ICU. Crit Care Clin 2005;21:239–249.
6.
Darmon M, Thiery G, Ciroldi M, Porcher R, Schlemmer B, Azoulay E: Should dialysis be offered to cancer patients with acute kidney injury? Intensive Care Med 2007;33:765–772.
7.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204–R212.
8.
Hoste EA, Schurgers M: Epidemiology of acute kidney injury: how big is the problem? Crit Care Med 2008;36:S146–S151.
9.
Bellomo R, Kellum JA, Ronco C: Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 2007;33:409–413.
10.
Ricci Z, Cruz D, Ronco C: The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008;73:538–546.
11.
Ostermann M, Chang RW: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007;35:1837–1843, quiz 1852.
12.
Jenq CC, Tsai MH, Tian YC, et al: RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. Intensive Care Med 2007;33:1921–1930.
13.
Brusselaers N, Monstrey S, Colpaert K, Decruyenaere J, Blot SI, Hoste EA: Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis. Intensive Care Med 2010;36:915–925.
14.
Daher EF, Marques CN, Lima RS, et al: Acute kidney injury in an infectious disease intensive care unit – an assessment of prognostic factors. Swiss Med Wkly 2008;138:128–133.
15.
Lin CY, Chen YC, Tsai FC, et al: RIFLE classification is predictive of short-term prognosis in critically ill patients with acute renal failure supported by extracorporeal membrane oxygenation. Nephrol Dial Transplant 2006;21:2867–2873.
16.
Soares M, Salluh JI, Carvalho MS, Darmon M, Rocco JR, Spector N: Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol 2006;24:4003–4010.
17.
Vieira JM, Castro I, Curvello-Neto A, et al: Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients. Crit Care Med 2007;35:184–191.
18.
Janus N, Launay-Vacher V, Byloos E, et al: Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 2010;103:1815–1821.
19.
Chawla LS, Abell L, Mazhari R, et al: Identifying critically ill patients at high risk for developing acute renal failure: a pilot study. Kidney Int 2005;68:2274–2280.
20.
Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL: Characteristics and outcomes of cancer patients in European ICUs. Crit Care 2009;13:R15.
21.
Samuels J, Ng CS, Nates J, et al: Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer. Support Care Cancer 2010, E-pub ahead of print.
22.
Elseviers MM, Lins RL, Van der Niepen P, et al: Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury. Crit Care 2010;14:R221.
23.
Pisoni R, Wille KM, Tolwani AJ: The epidemiology of severe acute kidney injury: from BEST to PICARD, in acute kidney injury: new concepts. Nephron Clin Pract 2008;109:c188–c191.
24.
Mehta RL, Pascual MT, Soroko S, Chertow GM, PICARD Study Group: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002;288:2547–2553.
25.
Maccariello E, Valente C, Nogueira L, et al: Outcomes of cancer and non-cancer patients with acute kidney injury and need of renal replacement therapy admitted to general intensive care units. Nephrol Dial Transplant 2011;26:537–543.
26.
Hoste EA, Clermont G, Kersten A, et al: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10:R73.
27.
Chen J, Singhapricha T, Hu KQ, et al: Postliver transplant acute renal injury and failure by the RIFLE criteria in patients with normal pretransplant serum creatinine concentrations: a matched study. Transplantation 2011;91:348–353.
28.
Lahoti A, Kantarjian H, Salahudeen AK, et al: Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 2010;116:4063–4068.
29.
Ando M, Mori J, Ohashi K, et al: A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT. Bone Marrow Transplant 2010;45:1427–1434.
30.
Soares M, Fontes F, Dantas J, et al: Performance of six severity-of-illness scores in cancer patients requiring admission to the intensive care unit: a prospective observational study. Crit Care 2004;8:R194–R203.
31.
Soares M, Silva UV, Teles JM, et al: Validation of four prognostic scores in patients with cancer admitted to Brazilian intensive care units: results from a prospective multicenter study. Intensive Care Med 2010;36:1188–1195.
32.
Groeger JS, Lemeshow S, Price K, et al: Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 1998;16:761–770.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.